Huang SM - Search Results

1

Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus.

Tucker GT, Houston JB, Huang SM. Tucker GT, et al. Among authors: huang sm. Br J Clin Pharmacol. 2001 Jul;52(1):107-17. doi: 10.1046/j.0306-5251.2001.temp.1441.x. Br J Clin Pharmacol. 2001. PMID: 11453898 Free PMC article. Review. No abstract available.

2

PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters.

Hsueh CH, Hsu V, Zhao P, Zhang L, Giacomini KM, Huang SM. Hsueh CH, et al. Among authors: huang sm. Clin Pharmacol Ther. 2018 Mar;103(3):485-492. doi: 10.1002/cpt.750. Epub 2017 Jul 24. Clin Pharmacol Ther. 2018. PMID: 28738449

3

PBPK model describes the effects of comedication and genetic polymorphism on systemic exposure of drugs that undergo multiple clearance pathways.

Vieira MD, Kim MJ, Apparaju S, Sinha V, Zineh I, Huang SM, Zhao P. Vieira MD, et al. Among authors: huang sm. Clin Pharmacol Ther. 2014 May;95(5):550-7. doi: 10.1038/clpt.2014.43. Epub 2014 Feb 20. Clin Pharmacol Ther. 2014. PMID: 24556783

4

Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor.

Vieira ML, Zhao P, Berglund EG, Reynolds KS, Zhang L, Lesko LJ, Huang SM. Vieira ML, et al. Among authors: huang sm. Clin Pharmacol Ther. 2012 Apr;91(4):700-8. doi: 10.1038/clpt.2011.305. Epub 2012 Mar 7. Clin Pharmacol Ther. 2012. PMID: 22398966

5

Transporter-mediated drug-drug interactions.

Zhang L, Huang SM, Lesko LJ. Zhang L, et al. Among authors: huang sm. Clin Pharmacol Ther. 2011 Apr;89(4):481-4. doi: 10.1038/clpt.2010.359. Clin Pharmacol Ther. 2011. PMID: 21423238

6

A regulatory viewpoint on transporter-based drug interactions.

Zhang L, Zhang YD, Strong JM, Reynolds KS, Huang SM. Zhang L, et al. Among authors: huang sm. Xenobiotica. 2008 Jul;38(7-8):709-24. doi: 10.1080/00498250802017715. Xenobiotica. 2008. PMID: 18668428 Review.

7

Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5.

Yoshida K, Sun B, Zhang L, Zhao P, Abernethy DR, Nolin TD, Rostami-Hodjegan A, Zineh I, Huang SM. Yoshida K, et al. Among authors: huang sm. Clin Pharmacol Ther. 2016 Jul;100(1):75-87. doi: 10.1002/cpt.337. Epub 2016 Mar 7. Clin Pharmacol Ther. 2016. PMID: 26800425 Free PMC article.

8

Intelligent pharmaceuticals: beyond the tipping point.

Honig P, Huang SM. Honig P, et al. Among authors: huang sm. Clin Pharmacol Ther. 2014 May;95(5):455-9. doi: 10.1038/clpt.2014.32. Clin Pharmacol Ther. 2014. PMID: 24747228

9

Transporters in drug development and clinical pharmacology.

Giacomini KM, Huang SM. Giacomini KM, et al. Among authors: huang sm. Clin Pharmacol Ther. 2013 Jul;94(1):3-9. doi: 10.1038/clpt.2013.86. Clin Pharmacol Ther. 2013. PMID: 23778703

10

The UCSF-FDA TransPortal: a public drug transporter database.

Morrissey KM, Wen CC, Johns SJ, Zhang L, Huang SM, Giacomini KM. Morrissey KM, et al. Among authors: huang sm. Clin Pharmacol Ther. 2012 Nov;92(5):545-6. doi: 10.1038/clpt.2012.44. Clin Pharmacol Ther. 2012. PMID: 23085876 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results